
May 9 (Reuters) - AstraZeneca PLC AZN.L:
IMFINZI® (DURVALUMAB) REGIMEN DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN DISEASE-FREE SURVIVAL FOR HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER IN POTOMAC PHASE III TRIAL
IMFINZI® (DURVALUMAB) REGIMEN DEMONSTRATED STATISTICALLY SIGNIFICANT AND CLINICALLY MEANINGFUL IMPROVEMENT IN DISEASE-FREE SURVIVAL FOR HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER IN POTOMAC PHASE III TRIAL